CME (CME) Q3 2024 Earnings Call Transcript

CME Group reported record Q3 results across revenue, net income, EPS, and ADV, with revenue nearly $1.6B (+18%), adjusted net income of $977M (+19%), EPS of $2.68 (+19%), and quarterly ADV of 28.3M contracts (+27%). Operating margin reached a record 69.1%, while management raised the full-year tax rate guidance to 22.5%-23% and highlighted continued strength in rates, international volumes, crypto, and energy. The call also emphasized ongoing monitoring of capital returns and M&A, plus regulatory risks around offshore Treasury clearing.

Analysis

CME is still operating like a toll road in a volatility supercycle, but the more interesting point is that the growth is increasingly self-reinforcing: client margin savings, tighter spreads, and cross-asset liquidity are creating switching costs that are harder for a new entrant to overcome than simple fee competition suggests. That matters because the current competitive challenge in SOFR is likely to stay economically noisy but strategically weak unless a rival can replicate both the spread advantage and the balance-sheet netting ecosystem; that is a tall bar, especially with clearing relationships and collateral optimization already embedded in client workflows.

The biggest second-order upside is not just rates volume, but the broadening of CME into a multi-on-ramp derivatives platform for retail and institutional flow. Retail adoption starts in equities, then migrates into commodities and rates as users mature; that creates a longer duration monetization curve than the market likely models, even if initial RPC is diluted. The key is that management is explicitly optimizing for revenue and earnings rather than per-contract yield, which suggests continued willingness to trade some unit economics for network expansion.

The main risk is not a near-term volume air pocket; it is a compression in the carry component of the business if the rate environment normalizes faster than expected, because today’s collateral economics are still benefiting from elevated balances and optimization. Separately, the Treasury clearing debate is a medium-term regulatory overhang: if policymakers accept the argument that resolution authority and capital requirements must sit onshore, that could structurally handicap offshore competitors and support CME’s moat; if they do not, the competitive landscape could become more price-elastic over 6-18 months. A less obvious contrarian takeaway is that the market may be underestimating how much of CME’s upside is now driven by international mix and product breadth rather than rate direction alone.

Key Decisions for Investors

• Go long CME on a 3-6 month horizon into any post-earnings consolidation; the setup favors multiple support from durable volume growth and operating leverage, with downside cushioned by recurring clearing/data revenue.
• Pair trade: long CME / short FMX for 1-2 quarters. FMX needs time to prove liquidity and client retention, while CME is monetizing network effects immediately; use the pair as a relative-value expression on SOFR competition.
• Buy CME Jan-2026 calls or call spreads if implied volatility is reasonable. The convexity here comes from upside surprise in retail adoption and cross-margining expansion, both of which are under-optionalized in the stock.
• If rates continue to fall and collateral yield pressure becomes visible, trim CME on rallies rather than chase. That is the main fundamental variable that could compress near-term earnings quality even if volumes remain strong.
• Watch for policy headlines on U.S. Treasury clearing over the next 1-2 quarters; any move that restricts offshore clearing economics should be bullish CME/LCH-sensitive rival risk and could widen CME’s strategic moat.